These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23010802)

  • 1. Activating CBL mutations are associated with a distinct MDS/MPN phenotype.
    Schwaab J; Ernst T; Erben P; Rinke J; Schnittger S; Ströbel P; Metzgeroth G; Mossner M; Haferlach T; Cross NC; Hochhaus A; Hofmann WK; Reiter A
    Ann Hematol; 2012 Nov; 91(11):1713-20. PubMed ID: 23010802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
    Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
    Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
    Martínez-Avilés L; Besses C; Álvarez-Larrán A; Torres E; Serrano S; Bellosillo B
    Ann Hematol; 2012 Apr; 91(4):533-41. PubMed ID: 21904853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.
    Fei F; Jariwala A; Pullarkat S; Loo E; Liu Y; Tizro P; Ali H; Otoukesh S; Amanam I; Artz A; Ally F; Telatar M; Nakamura R; Marcucci G; Afkhami M
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Patnaik MM; Lasho TL
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia.
    Kao HW; Sanada M; Liang DC; Lai CL; Lee EH; Kuo MC; Lin TL; Shih YS; Wu JH; Huang CF; Ogawa S; Shih LY
    Neoplasia; 2011 Nov; 13(11):1035-42. PubMed ID: 22131879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
    Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
    Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
    Makishima H; Cazzolli H; Szpurka H; Dunbar A; Tiu R; Huh J; Muramatsu H; O'Keefe C; Hsi E; Paquette RL; Kojima S; List AF; Sekeres MA; McDevitt MA; Maciejewski JP
    J Clin Oncol; 2009 Dec; 27(36):6109-16. PubMed ID: 19901108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.
    Muto T; Sashida G; Oshima M; Wendt GR; Mochizuki-Kashio M; Nagata Y; Sanada M; Miyagi S; Saraya A; Kamio A; Nagae G; Nakaseko C; Yokote K; Shimoda K; Koseki H; Suzuki Y; Sugano S; Aburatani H; Ogawa S; Iwama A
    J Exp Med; 2013 Nov; 210(12):2627-39. PubMed ID: 24218139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.
    Schnittger S; Bacher U; Alpermann T; Reiter A; Ulke M; Dicker F; Eder C; Kohlmann A; Grossmann V; Kowarsch A; Kern W; Haferlach C; Haferlach T
    Haematologica; 2012 Dec; 97(12):1890-4. PubMed ID: 22733026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2
    Todisco G; Creignou M; Gallì A; Guglielmelli P; Rumi E; Roncador M; Rizzo E; Nannya Y; Pietra D; Elena C; Bono E; Molteni E; Rosti V; Catricalá S; Sarchi M; Dimitriou M; Ungerstedt J; Vannucchi AM; Hellström-Lindberg E; Ogawa S; Cazzola M; Malcovati L
    Leukemia; 2021 Aug; 35(8):2371-2381. PubMed ID: 33349666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
    Palomo L; Meggendorfer M; Hutter S; Twardziok S; Ademà V; Fuhrmann I; Fuster-Tormo F; Xicoy B; Zamora L; Acha P; Kerr CM; Kern W; Maciejewski JP; Solé F; Haferlach C; Haferlach T
    Blood; 2020 Oct; 136(16):1851-1862. PubMed ID: 32573691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
    Tiu RV; Sekeres MA
    Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
    Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
    Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
    Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
    Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.
    Bacher U; Haferlach C; Schnittger S; Kohlmann A; Kern W; Haferlach T
    Ann Hematol; 2010 Jul; 89(7):643-52. PubMed ID: 20195608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo childhood myelodysplastic/myeloproliferative disease with unique molecular characteristics.
    Ismael O; Shimada A; Hama A; Elshazley M; Muramatsu H; Goto A; Sakaguchi H; Tanaka M; Takahashi Y; Yinyan X; Fukuda M; Miyajima Y; Yamashita Y; Horibe K; Hanada R; Ito M; Kojima S
    Br J Haematol; 2012 Jul; 158(1):129-37. PubMed ID: 22571758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis.
    Aoyama Y; Sakai K; Kodaka T; Tsunemine H; Nishio K; Itoh T; Inoue D; Takahashi T
    J Clin Exp Hematop; 2019 Mar; 59(1):29-33. PubMed ID: 30726782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.